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Abstract: NCCN Guidelines recommend BRCA genetic testing in individuals with a probability
>5% of being a carrier. Nonetheless, the cost-effectiveness of testing individuals with no tumor
family history is still debated, especially when BRCA testing is offered by the national health
service. Our analysis evaluated the rate of BRCA pathogenic or likely-pathogenic variants in 159
triple-negative breast cancer (TNBC) patients diagnosed ≤60 years, and 109 luminal-like breast cancer
(BC) patients diagnosed ≤35 without breast and/or ovarian family histories. In TNBC patients, BRCA
mutation prevalence was 22.6% (21.4% BRCA1). Mutation prevalence was 64.2% ≤30 years, 31.8%
in patients aged 31–40, 16.1% for those aged 41–50 and 7.9% in 51–60 s. A total of 40% of patients
with estrogen receptors (ER) 1–9% were BRCA1 carriers. BRCA detection rate in early-onset BCs was
6.4% (4.6% BRCA2). Mutation prevalence was 0% between 0–25 years, 9% between 26–30 years and
6% between 31–35 years. In conclusion, BRCA testing is recommended in TNBC patients diagnosed
≤60 years, regardless of family cancer history or histotype, and by using immunohistochemical
staining <10% for both ER and/PR. In luminal-like early-onset BC, a lower BRCA detection rate was
observed, suggesting a role for other predisposing genes along with BRCA genetic testing.
Keywords: BRCA; family history; genetic testing; triple-negative; early-onset; breast cancer
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1. Introduction
First- and second-degree relatives of breast cancer (BC) patients present an increased risk for this
malignancy. In particular, these individuals may have an increased susceptibility to cancer as a result
of gene mutations present in parental germline cells. Tumors developing in these families are classified
as hereditary cancers, and the most frequently involved predisposition genes include BRCA1 and
BRCA2. Overall, BRCA1/2-positive families present an increased incidence of breast, ovarian, prostate
and pancreatic cancers [1–4]. Assessment of an individual’s risk for hereditary tumors is therefore
based on a thorough evaluation of personal and family cancer history.
The identification of a mutation in BRCA genes plays a crucial role in the management of hereditary
cancer prevention, diagnosis and treatment [2,5–10]. Nonetheless, because of the high costs associated
with genetic analyses, especially in those countries where BRCA testing is offered by the national health
service, BRCA testing has been restricted to BC patients having an a priori high risk of being carriers
or candidates for approved targeted treatment strategies (i.e., PARP inhibitors [11]). In particular,
according to the National Institute for Health and Care Excellence (NICE) in the UK, BRCA testing
should be offered to BC patients with a probability of mutation≥10% [12]. On the other hand, according
to the recent update of NCCN guidelines [13], BRCA genetic testing is clinically recommended in
individuals with a probability >5% based on prior probability models (e.g., Tyrer-Cuzik, BRCAPro etc).
Several international oncology associations, such as ESMO, ASCO, NCCN etc., provide guidelines
for BRCA testing based on the clinical–pathological characteristics of tumors and family cancer histories.
On these grounds, in individuals potentially meeting established criteria for hereditary cancer syndrome,
genetic testing is performed beginning with an appropriate examination of family history. Indeed,
effective pretest counseling includes the development of an expanded pedigree that collects the health
status of individuals diagnosed with cancer and first-, second- and third-degree relatives on both
maternal and paternal sides. Nevertheless, several factors may limit the informativeness of the pedigree,
such as small family size, a small number of individuals from the susceptible gender for sex-limited
cancers, reduced penetrance, early deaths in family members, prophylactic surgeries that remove
an organ due to subsequent cancer risk, adoptions, and inaccurate or incomplete information on
family members [14,15]. Consequently, other factors should be considered during genetic counseling,
including biology and age at diagnosis of the tumors developed by the counseled patient. In particular,
the Italian Association of Medical Oncology (AIOM) guidelines include the personal history of
triple-negative BC (TNBC) patients diagnosed ≤60 years and the personal history of early onset breast
cancer (EOBC) patients diagnosed ≤35 years, regardless of family history [16], among the BRCA
testing criteria.
With the aim to evaluate the weight of clinical–pathological characteristics compared to tumor
family histories, we evaluated the prevalence of BRCA germline mutations in an Italian cohort of
TNBC and luminal-like EOBC patients without breast/ovarian cancer family histories.
2. Results
2.1. Triple-Negative Breast Cancer
Among 523 unselected TNBC patients diagnosed ≤60 years undergoing BRCA genetic testing at
the MFCC, a total of 159 TNBC patients without BC and/or OC family histories were identified in our
archives (Table 1). The prevalence of germline BRCA pathogenic or likely-pathogenic variants in the
entire population of TNBC patients was 99/523 (18.9%), while the proportion among patients without a
family history was 36/159 (22.6%). The BRCA detection rate was not significantly different between
unselected TNBC patients and TNBC patients without a family history (p = 0.30).
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Table 1. Characteristics of triple-negative breast cancer patients.
TNBC Negative BRCA1 BRCA2 p-Value
Number of patients (159) 123 34 2 * **
Mean age at diagnosis (y) 44.78 (24–59)SD 9.07
36.97 (26–54)
SD 8.74
45.00 (39–51)
SD 8.48 0.004 <0.001
Age group (y)
<0.001 <0.001
≤30 5 (4.0%) 9 (26.5%) 0
31–40 31 (25.2%) 13 (38.3%) 1 (50%)
41–50 52 (42.3%) 10 (29.4%) 0
51–60 35 (28.5%) 2 (5.9%) 1 (50%)
Ki 67 (%)
0.508 0.462
≤20 11 (10.1%) 1 (3.3%) 0
>20 98 (89.9%) 29 (96.7%) 1 (100%)
unknown 14 4 1
Bilaterality
0.193 0.088
Yes 5 (4.2%) 4 (12.9%) 0
No 114 (95.7%) 27 (87.1%) 2 (100%)
unknown 4 3 0
Histotype
0.466 0.301
ductal 103 (95.4%) 28 (90.3%) 2 (100%)
lobular 0 1 (3.2%) 0
others 5 (4.6%) 2 (6.5%) 0
unknown 15 3 0
RO
0.321 0.226
negative 116 (95.1%) 30 (88.2%) 2 (100%)
1–9 % 6 (4.9%) 4 (11.8%) 0
unknown 1 0 0
* Comparison Negative vs. BRCA1 vs. BRCA2; ** Comparison Negative vs BRCA1.
Among TNBC patients without a family history, 34 patients presented a BRCA1 pathogenic or
likely-pathogenic variant (21.4%), whereas 2 patients were BRCA2 carriers (1.2%). BRCA1-positive
TNBC patients were diagnosed at a younger age (37 years) than noncarriers (44 years) or BRCA2 carriers
(45 years) (p< 0.001). Mutation prevalence in TNBC patients was 9/14 (64.2%) in the age group≤30 years,
14/44 (31.8%) in 31–40 years, 10/62 (16.1%) in 41–50 years and 3/38 (7.9%) in 51–60 years (Figure 1).
As expected, most of the TNBCs present a high proliferation rate and ductal histotype. Only one
invasive lobular carcinoma was recorded and was categorized as BRCA1-associated. Moreover, three
metaplastic carcinomas, two medullary, one sarcomatoid and one papillary tumor were diagnosed,
and among these, one medullary and one papillary were diagnosed in BRCA1 carriers. Ten out of
159 patients presented ER and/or PR between 1% and 9%, and four of these (40%) were BRCA1 carriers.
In particular, two of these patients were diagnosed at age 26 years old, one patient at 32 years and one
patient at 56 years. No significant differences were observed between BRCA1 carriers and noncarriers
in clinical and pathological characteristics such as ki-67 (p = 0.462), the presence of bilateral or second
primary BC (p = 0.088), histotype (p = 0.301) or hormone receptor expression (p = 0.226).
Fourteen out of 159 patients (8.8%) presented a family history of pancreatic cancer. In particular,
five women (two of which BRCA1 carriers) presented a first-degree relative affected by pancreatic
cancer and eight women (two of which BRCA1 carriers) presented a second-degree relative with
pancreatic cancer. Moreover, 22 out of 159 patients (13.8%) reported family history for prostate
cancer. In detail, 6 women had a first-degree relative, 13 women (two of which BRCA1 carriers) had
a second-degree relative, while 3 women (one BRCA1 carrier) presented two first or second-degree
relatives affected by prostate cancers. In conclusion, the BRCA detection rate in TNBC patients with a
family history of pancreatic cancer was 28.6%, whereas BRCA prevalence in women with both TNBC
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and a family history of prostate cancer was 13.6%. In both cases, the BRCA detection rate did not
significantly differ from that of patients with pancreatic or prostate cancer family histories.
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Figure 1. BRCA detection rate (%) in triple-negative breast cancer patients divided according to age at
diagnosis (less than 30, 31–40, 41–50 and 51–60 years old).
2.2. Early-Onset Luminal-like Breast Cancer
Among 646 nselected luminal-lik EOBC patients undergoing BRCA genetic testing at the MFCC,
a total of 109 luminal-like EOBC patients with no BC/OC family history were identified in our archives
(Table 2). The BRCA detection rate among the entire population of luminal-like EOBC patients was
136/646 (21%), while the rate among EOBCs without a family history was 7/109 (6.4%). The BRCA
detection rate in unselected luminal-like EOBC patients was significantly higher than in luminal-like
EOBC patients without a family history (p = 0.0003).
Among luminal-like EOBC patients without a family history, two patients presented a BRCA1
pathogenic or likely-pathogenic variant (1.8%), whereas five patients were BRCA2 carriers (4.6%).
The mutation prevalence was 0/5 (0%) in the age group 0–25 years, 2/22 (9%) between 26 and 30 years,
and 5/82 (6%) in the age group 31–35 years (Figure 2). Most patients were diagnosed with an invasive
ductal carcinoma (in particular, 91.3% of the BRCA-negative patients and all BRCA-positive patients).
One tubular, one papillary and one mucinous carcinoma were also diagnosed, all of them in patients
who had test d e ative for BRCA pathogenic or likely-pathogenic variants. No significant differences
in age at diagnosis (p = 0.488), ki-67 (p = 0.920), presence of bilateral or second primary BC (p = 0.249),
histotype (p = 1.00), PR ( = 0.105) or HER2 expression (p = 0.052) were observed.
Twelve out of 109 luminal-like EOBC patients (11%) presented a family history of pancreatic cancer.
In particular, two women presented a first-degree relative, nine women (one BRCA2 carrier) presented a
second-degree relative and one patient had one third-degree relative with pancreatic cancer. Moreover,
10 out of 109 patients (9.2%) reported a family history of prostate cancer. In detail, two women had a
first-degree relative, six women (one BRCA2 carrier) had a second-degree relative, while two women
presented two first or second-degree relatives affected by prostate cancers. In conclusion, the BRCA
detection rate in luminal-like EOBC patients with a family history of pancreatic cancer was 8.3%,
whereas BRCA prevalence in women with both luminal-like EOBC and a family history of prostate
cancer was 10%. In both cases, the BRCA detection rate did not significantly differ from that of patients
with pancreatic or prostate cancer family histories.
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Table 2. Characteristics of luminal-like early onset breast cancer patients.
EOBC Negative BRCA1 BRCA2 p-Value
Number of patients (109) 102 2 5 *
Mean age at diagnosis (y) 31.95 (23–35)SD 2.85
34.0 (33–35)
SD 2.93
30.6 (27–33)
SD 2.89 0.488
Age group (y)
0.688
≤25 5 (4.9%) 0 0
26–30 20 (19.6%) 0 2 (40%)
31–35 77 (75.5%) 2 (100%) 3 (60%)
Ki 67 (%)
0.920
≤20 35 (44.9%) 0 2 (50%)
>20 43 (55.1%) 1 (100%) 2 (50%)
unknown 24 1 1
Bilaterality
0.249
Yes 5 (5.3%) 1 (50%) 0
No 90 (94.7%) 1 (50%) 5 (100%)
unknown 7 0 0
Histotype
1.00
ductal 74 (91.3%) 2 (100%) 4 (100%)
lobular 3 (3.7%) 0 0
others 4 (4.9%) 0 0
unknown 21 0 1
PR
0.105
≤20 29 (33.7%) 0 2 (40%)
>20 57 (66.3%) 0 3 (60%)
unknown 23 2 0
HER2
0.052
negative 54 (69.2%) 0 5 (100%)
positive 24 (30.8%) 0 0
unknown 24 2 0
* Comparison Negative vs. BRCA1 vs. BRCA2.
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3. Discussion 
Figure 2. BRCA detection rate (%) in luminal-like early-onset breast cancer patients divided according
to age at diagnosis (less than 25, 26–30 and 31–50 years old).
3. Discussion
According to the recommendations of all international oncology associations, BRCA genetic
testing criteria are based on the clinical–pathological characteristics of personal tumor and family
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cancer histories. Pretest counseling is performed beginning with a thorough examination of family
history. It is commonly thought that hereditary cancers should develop in the context of a family
seriously affected by the same disease. Nevertheless, several factors may limit the informativeness of
the pedigree, such as inaccurate or incomplete information on family members, while our patient’s
cancer could be the first in the family. Indeed, a prospective study of 306 women diagnosed with
breast cancer at <50 years of age, with no first or second-degree relatives with breast or ovarian cancer,
showed that those individuals with a limited family history may have an underestimated probability
of BRCA mutation, based on models relying exclusively on family history [17]. Moreover, mainstream
test models characterized by few cancer-based criteria and provided directly by the cancer team instead
of referring patients to the genetics department were demonstrated to efficiently deliver consistent and
cost-effective BRCA testing [18]. Many authors highlight the need to increase our efforts in order to
identify as many mutation carriers as possible, especially mutations in high-penetrance genes such as
BRCA1 and BRCA2, possibly through national population testing programs [19]. Nevertheless, while
we continue to wait for modelling, health economic and pilot implementation studies for population
genetic testing, BRCA testing criteria are nowadays still needed, especially in countries where the test
is offered by public health services.
Previous research helped to define the clinical–pathological characteristics of BRCA-related tumors.
In detail, BRCA1-associated tumors are poorly differentiated infiltrating carcinomas, more frequently
ER- and PR-negative and p53-positive [20,21]. On the other hand, BRCA2-associated BC tends to be of
higher grade than sporadic age-matched controls [22]. Overall, BRCA-associated BCs are diagnosed at
a young age and show a low frequency of HER2 expression [21,23]. On these grounds, international
guidelines included the presence of young age at diagnosis and TN profile, regardless of family history,
in the BRCA genetic testing criteria. Our study aimed to evaluate the rate of BRCA pathogenic or
likely-pathogenic variants in patients selected according to the biology and age of diagnosis of their
tumors, in the absence of cancer family history.
Our analyses indicated a high mutation rate (22.6%) in the overall population of TNBC patients
diagnosed ≤60 years without BC and/or OC in their family history. In detail, BRCA testing was deemed
cost-effective up to 50 years according to the NICE guidelines, while in the subgroup of patients
diagnosed between 51 and 60 years, detection rate was 7.9%, and was still cost-effective according to the
last NCCN guidelines. Interestingly, the BRCA detection rate was not significantly different between
unselected TNBC patients and TNBC patients without a family history (p = 0.30). Overall, our results
show some discrepancies from the previous literature. Indeed, according to the literature, 15–30%
of unselected TNBCs had confirmed BRCA mutations [24–26]. Conversely, mutation prevalence
decreased to 6–15% in patients without breast/ovarian cancer family histories [25,27]. The high BRCA
mutation prevalence in our population could be explained by the fact that 37.1% of our patients were
diagnosed ≤40 and 76.1% ≤ 50. Young age at diagnosis could therefore have increased the rate of
BRCA detection compared to previous publications. Particularly, the high rate of young TNBC patients
in our population could be explained by the fact that TNBC is more common in young patients and,
until 2016, we only tested patients diagnosed ≤40 years. Finally, according to the literature, the BRCA1
patients in our study were diagnosed at a younger age than noncarriers.
Interestingly, despite the cut-off for hormone–receptor negativity defined by the ASCO–CAP
guidelines [28], 40% of the patients with ER between 1% and 9% (ER low positive) were observed
to be BRCA1-positive at genetic testing. Previous analyses have already highlighted that tumors
with ER < 10% clinically behave as ER < 1% tumors [29]. Along with the results presented in this
paper, these data indicate that, for clinical purposes, HER2-negative tumors with ER < 10% should be
considered as TNBC. Furthermore, as reported in other analyses [19], 3 out of 34 (8.8%) BRCA1-related
tumors presented a rarer non-ductal histotype (in our study, one medullary, one papillary and one
lobular). Finally, no differences were observed between carriers and noncarriers in the proliferation
rate and the presence of bilateral tumors or second primary BC. Since 2013, patients at our Family
Cancer Clinic have been offered rapid genetic counseling and testing at BC diagnosis. This strategy was
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demonstrated to improve the rate of risk-reducing bilateral mastectomy at the time of BC surgery [30],
enabling us to reduce the risk of contralateral tumors in BRCA carriers. Nevertheless, it is noteworthy
that in the prospective POSH study, immediate bilateral mastectomy was not associated with improved
survival. Hence, decisions about the timing of additional surgery aimed at reducing second primary
cancer risks should still give priority to patient prognosis associated with the first malignancy and
patient preferences [31].
In the second part of our analysis, we evaluated 109 patients diagnosed with luminal-like BC at
≤35 years without a family history of BC and/or OC. To our knowledge, this is the first study to evaluate
the rate of BRCA mutation in luminal-like EOBC patients with no family history. This analysis is even
more valuable in light of the EMBRACA trial results, in which talazoparib provided a significant PFS
improvement over standard chemotherapy in patients with BRCA-related HER2-negative advanced
breast cancer, at the same level in both TNBC and hormone-receptor-positive subtypes [32]. Overall,
and in each age subgroup (≤25, 26–30 and 31–35), the BRCA detection rate was less than 10% (6.4%, 0%,
9% and 6%, respectively). Interestingly, all the patients diagnosed with EOBC under 26 years were
observed to be negative at genetic testing, possibly underlining the need to evaluate other predisposing
factors. In our population, the presence of BC and/or OC family history was demonstrated to
significantly increase BRCA detection rate, which was 21% in unselected luminal-like EOBC patients
and 24% in patients with family histories. No difference in proliferation rate was observed between
carriers and noncarriers, contrary to what is reported in the literature [22]. Finally, as expected, most of
hereditary luminal-like EOBCs were BRCA2-associated and HER2/neu-negative, and all of them were
to be accounted for as ductal carcinoma.
4. Materials and Methods
4.1. Study Population and Design
Since 1995, the Modena Family Cancer Clinic (MFCC) has offered genetic counseling to women
with a personal or family history of BC and/or OC. In particular, healthy women with a family
history are referred to the MFCC by their general practitioners or the radiologists that perform their
population-based screening mammography. On the other hand, BC and OC patients are referred to
the MFCC by their oncologists, radiologists, surgeons or gynecologists. During the first counseling
visit at the clinic, women are classified in risk categories according to the Modena Criteria [33,34] and,
more recently, using the Tyrer–Cuzick model [35], and are finally included in personalized surveillance
programs. Moreover, individuals who meet the AIOM Criteria for genetic testing can undergo the
BRCA test. Then, according to the result, they may access risk-reducing surgeries [30], chemoprevention
studies [9] or more intensive surveillance programs [6,7]. During pretest counseling, family and
personal histories of cancer are collected and a family pedigree is drawn including third-degree
relatives on both maternal and paternal sides. Finally, after post-test counseling, a copy of all patient
documents and reports are stored in the MFCC archive.
For the purpose of our study, we retrospectively revised the 7690 family pedigrees stored in our
archive and identified patients with TNBC diagnosed ≤60 years and luminal-like EOBC diagnosed ≤35
with neither breast nor ovarian family histories. The MFCC began to test all EOBC patients in 1998,
whereas TNBC patients younger than 40 years have been tested since 2006. Only in 2016, the indication
to genetic testing was extended to 60 years at TNBC diagnosis.
ER, PR and HER2 expression was determined according to the national pathology guidelines,
which closely adhere to international standards. For the clinical purpose of our study, triple
negativity was defined as immunohistochemical staining of less than 10% of nuclei for both ER
and PR, and an immunohistochemical result (DAKO score) of 0 or 1+ for HER2/neu or 2+ and
DDISH/FISH-negative. Systematic evaluation of HER2 status became available in our institution
only in 2006, when Trastuzumab was approved in the adjuvant setting. Hence, in our study, only
triple-negative BC patients diagnosed from 2006 or with already performed retrospective HER2
Cancers 2020, 12, 1252 8 of 11
evaluation were included. With regard to the luminal-like group, on the other hand, we included
tumors with immunohistochemical staining of at least 10% of nuclei for ER.
4.2. BRCA Testing Procedures
Before 2014, the genetic testing of BRCA1 and BRCA2 genes at our institution was carried out by
direct Sanger sequencing, whilst it was performed using next-generation sequencing (NGS) after 2014.
With both methods, the molecular test was performed on genomic DNA, isolated from fresh peripheral
blood samples and encompassing the entire coding region as well as the adjacent intronic splice-site
consensus sequences of BRCA genes. The NGS workflow benefited from the use of the Ion AmpliSeqTM
technology, which was initially handled with a semi-automated procedure, and subsequently with
a fully automated procedure for multiplex PCR-based library preparation and sequencing on the
Ion Torrent platforms (Thermo Scientific). Sanger sequencing was routinely performed to validate
candidate pathogenic or likely-pathogenic variants, as long as Multiplex Ligation Probe Amplification
(MLPA, MRC-Holland) was carried out to detect copy number variations. NGS sequence alignment,
base and variant calling relied on the Torrent Software Suite (Thermo Scientific) updated to the last
available version at the time of sequencing, as well as the annotation process, which was also integrated
with open source bioinformatics tools, customized and validated in the laboratory (Annovar [36] and
Variant Effect Predictor, [37]) as described elsewhere [38,39]. For the purpose of this study, variants of
unknown significance were considered as clinically negative results. Variants classified as pathogenic
or likely-pathogenic at the time of diagnosis were re-evaluated at the time of manuscript writing
according to the ACMG criteria (American College of Medical Genetics and Genomics) [40] for possible
classification updating. All the variants classified as pathogenic or likely-pathogenic were recognized
as such.
4.3. Statistical Analysis
Mutation prevalence and clinical–pathological characteristics were evaluated for each subgroup
of patients. Patient characteristics and the distribution of each parameter across subgroups were
reported as absolute and percentage frequencies. A comparison between groups was made by means
of Fischer’s exact test. Statistical analyses were conducted using IBM SPSS Statistics for Windows
Version 23.0 (IBM Corporation, Armonk, NY, USA). P-values < 0.05 were considered significant.
5. Conclusions
According to the last NCCN Guidelines, the results of our study confirm the recommendation to
test for BRCA genes in TNBC patients ≤ 60 years, regardless of family history, tumor histotype and
by using immunohistochemical staining of less than 10% of nuclei for both ER and/PR as a cut-off.
In luminal-like EOBC patients with no BC and/or OC family history, on the other hand, a lower overall
BRCA detection rate was observed of >5%, suggesting a role for testing other predisposing genes
along with BRCA1 and BRCA2 in this subset of patients. Finally, in both TNBC and luminal-like EOBC
groups, the presence of pancreatic or prostate cancers in family histories did not significantly modify
the BRCA detection rate.
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